73,95 €
73,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
37 °P sammeln
73,95 €
73,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
37 °P sammeln
Als Download kaufen
73,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
37 °P sammeln
Jetzt verschenken
73,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
37 °P sammeln
  • Format: PDF

This book offers a comprehensive evaluation of the use of stereotactic body radiosurgery (SBRT) for the treatment of prostate cancer. The rationale, selection criteria, and treatment planning for prostate SBRT are explained. Important imaging and anatomic considerations are discussed, and detailed consideration devoted to organ motion and tumor tracking during SBRT. Outcomes of therapy are then examined, with thorough appraisal of side effect profiles and quality of life impacts. Clear guidance is provided on how to deliver the therapy in a way that minimizes the risk of long-term urinary and…mehr

Produktbeschreibung
This book offers a comprehensive evaluation of the use of stereotactic body radiosurgery (SBRT) for the treatment of prostate cancer. The rationale, selection criteria, and treatment planning for prostate SBRT are explained. Important imaging and anatomic considerations are discussed, and detailed consideration devoted to organ motion and tumor tracking during SBRT. Outcomes of therapy are then examined, with thorough appraisal of side effect profiles and quality of life impacts. Clear guidance is provided on how to deliver the therapy in a way that minimizes the risk of long-term urinary and rectal toxicities.

Stereotactic radiosurgery for prostate cancer is an increasingly used form of treatment. Retrospective investigations have demonstrated the safe application of high-dose treatments, with 5-year results comparable to those achieved with protracted external beam radiotherapy. Prospective studies are underway comparing SBRT with more traditional forms of image-guided andintensity-modulated radiotherapy. In offering in-depth guidance on safe delivery of prostate SBRT, this book will be of value for students of radiation oncology, more experienced practitioners, and medical physicists.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Professor Michael Zelefsky is a recognized international authority in the treatment of prostate cancer with radiotherapy. He is currently Vice Chair of the Department of Radiation Oncology and Chief of the Brachytherapy Service at Memorial Sloan Kettering Cancer Center. He also serves as a leader of the Genito-urinary Disease Management Team at Memorial Sloan Kettering and has been instrumental in the development of novel radiation techniques that have been adopted worldwide, including IMRT, IGRT, and intraoperative adaptive brachytherapy treatment planning. Professor Zelefsky has published more than 300 publications as well as chapters and textbooks. He is currently exploring approaches using targeted biologic agents concurrently with hypofractionated stereotactic radiosurgery for high-risk disease as well as the implementation of novel brachytherapy techniques to improve the precision of brachytherapy in the treatment of prostate cancers.  Dr. Zelefsky is the Editor inChief of Brachytherapy, the premier journal in the world for articles devoted to the use of brachytherapy in the treatment of cancer.
Rezensionen
"This is a highly focused, thorough review of the current status of SBRT in the treatment of prostate cancer. It details key factors that need to be considered to achieve optimal outcomes. Of note, several of these factors, such as optimizing target definition and minimizing organ motion, are pertinent for a broader range of prostate cancer patients and, as such, will appeal to readers seeking a better broad understanding of these topics." (Mark D. Hurwitz, Doody's Book Reviews, February, 2019)